$JNJJOHNSON & JOHNSON

📅 Upcoming

🕒 Recent(90d)

News

• Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
  The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
  biopharma_dive · 20h ago
• BMS welcomes new multiple myeloma drug as generics batter current portfolio
  The FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…
  biospace · 1d ago
• Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board
  → Some big changes are coming at Bicara Therapeutics, and it starts at the top. President and COO Ryan Cohlhepp will take over as CEO on Jan. 1, and Claire Mazumdar ...
  endpoints · 1d ago
• New Taiho, Cullinan data heats up lung cancer drug battle
  The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
  biopharma_dive · 1d ago
• Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
  Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
  biospace · 1d ago
• MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
  Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…
  fiercebiotech · 2d ago
• Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
  As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
  fiercebiotech · 2d ago
• Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
  Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
  biopharma_dive · 3d ago
• BMS picks Texas for new $2.3B manufacturing campus
  Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
  biospace · 4d ago